Importance of heterotrimeric G proteins in prostate cancer molecular biology;Importancia de las proteínas G heterotriméricas en la biología molecular del cancer de próstata

Actas Urologicas Espanolas

Volumn 29, Issue 10, 2005, Pages 948-954

  Prieto Villapun, J C ^a   Solano Haro, R M ^a   Carmena Sierra, M J ^a   Sanchez Chapado M ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Expression; G proteins; Mutations; Prostate cancer

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT;

ADENOCARCINOMA; AGED; ARTICLE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS;

EID: 33645459515     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(05)73375-1     Document Type: Article

References (25)

1. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni Mr, Hamm HE. Insights into G protein structure, function, and regulation. Endocr Rev 2003;24:765-781.
2. Offermanns S. G-proteins as transducers in transmembrane signalling. Progr Biophys Mol Biol 2003;83:101-130.
3. Spiegel AM, Weinstein LS. Inherited diseases involving G proteins and G protein-coupled receptors. Ann Rev Med 2004;55:27-39.
4. Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T. Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab 2003;14:431-437.
5. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Therap 2003;99:25-44.
6. Hepler JR. RGS proteins and G protein interactions: a little help from their friends. Mol Pharmacol 2003;64:547-549.
7. Albert PR, Robillard L. G protein specificity: traffic direction required. Cell Signal 2002;14:407-418.
8. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002;31:1636-1639.
9. Rashid AJ, O'dowd BF, George SR. Minireview: Diversity and complexity of signalling through peptidergic G protein-coupled receptors. Endocrinology 2004;145:2645-2652.
10. Liebmann C. G protein-coupled receptors and their signalling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des 2004; 10:1937-1958.
11. Dumont JE, Jauniaux JC, Roger PP. The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci 1989;14:67-71.
12. Vallar L. Oncogenic role of heterotrimeric G proteins. Cancer Surv 1996;27:325-338.
13. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med 2003; 228:1004-1017.
14. α and stimulate adenylyl cyclase in human pituitary tumors. Nature 1989;340:692-696.
15. Pace AM, Wong YH, Bourne HR. A mutant alpha subunit of Gi2 induces neoplastic transformation of Rat-1 cells. Proc Natl Acad Sci USA 1991;88:7031-7035.
16. Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, Mccormick F. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655-659.
17. Gupta SK, Gallego C, Lowndes JM, Pleiman CM, Sable C, Eisfelder BJ, Johnson GL. Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Mol Cell Biol 1992;12, 190-197.
18. Logothetis CJ. Prostate Cancer I. Sem Oncol 1999;26:139-248.
19. Logothetis C.J. Prostate Cancer II. Sem Oncol 1999;26: 369-474.
20. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274:7777-7788.
21. Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000;164:2162-2167.
22. α protein subunits in human prostate cancer. J Urol 2001;166:2512-2517.
23. Daaka Y. G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004;13: 216.
24. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Román F, Hueso C, Travail S, López-Fraile N, Guijarro LG, Prieto JC. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996;137: 2815-2822.
25. Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate. Cell Signal 1999;11:813-819.